Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 21-2024 (Fed. Cir. Feb. 15, 2022) — Rule 36 Judgment

NOTE: This disposition is nonprecedential. United States Court of Appeals

for the Federal Circuit

AMARIN PHARMA, INC., AMARIN

PHARMACEUTICALS IRELAND LIMITED,

Plaintiffs

EPA DRUG INITIATIVE II,

Movant-Appellant

HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED,

WEST-WARD PHARMACEUTICALS

INTERNATIONAL LIMITED, DR. REDDY'S

LABORATORIES, INC., DR. REDDY'S

LABORATORIES, LTD.,

Defendants-Appellees

2021-2024

Appeal from the United States District Court for the District of Nevada in Nos. 2:16-cv-02525-MMD-NJK, 2:16-cv-02562-MMD-NJK, Judge Miranda M. Du.

JUDGMENT

2MICHAEL S. KASANOFF, I, Michael S. Kasanoff, LLC, Matawan, NJ, argued for movant-appellant. CHARLES B. KLEIN, Winston & Strawn LLP, Washington, DC, for defendants-appellees Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited, West-Ward Pharmaceuticals International Limited. Also represented by CLAIRE A. FUNDAKOWSKI; ALISON MICHELLE KING, Chicago, IL; EIMERIC REIG-PLESSIS, San Francisco, CA.

JAMES BARABAS, Windels Marx Lane & Mittendorf, LLP, Madison, NJ, argued for all defendants-appellees. Defendants-appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. also represented by BETH C. FINKELSTEIN, CONSTANCE HUTTNER, CAROLINE SUN.

THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED:

PER CURIAM (NEWMAN, DYK, and REYNA, Circuit

Judges).

AFFIRMED. See Fed. Cir. R. 36.

ENTERED BY ORDER OF THE COURT

February 15, 2022 /s/ Peter R. Marksteiner

Date Peter R. Marksteiner

Clerk of Court

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

ENTERED BY ORDER OF THE COURT

Cite this opinion